文献速递心血管CTPET

依洛尤单抗对冠状动脉斑块成分及冠状动脉PET与CT血管造影所示微钙化活性的影响

Effects of Evolocumab on Coronary Plaque Composition and Microcalcification Activity by Coronary PET and CT Angiography.
PubMed 文献 · JACC Cardiovasc Imaging · 2025-04-02

这项单臂前瞻性开放标签研究纳入47例基线冠状动脉CTA显示广泛非钙化斑块的患者,给予依洛尤单抗治疗18个月。随访显示非钙化斑块及低衰减非钙化斑块体积显著减少,钙化斑块体积增加,冠状动脉微钙化活性及病灶靶本比显著降低,总斑块体积无显著变化。

要点

  • 基线广泛非钙化斑块患者经依洛尤单抗治疗18个月后非钙化斑块体积显著减少(P<0.001)。
  • 低衰减非钙化斑块体积显著减少(P<0.001),钙化斑块体积显著增加(P<0.001)。
  • 18F-NaF PET示冠状动脉微钙化活性及病灶靶本比均显著降低(P=0.004与P=0.005)。

核心结论

  • 在基线广泛非钙化斑块的稳定患者中,依洛尤单抗治疗18个月与斑块定量表型向较低风险方向转变及微钙化活性降低相关。

研究设计与样本

  • 单臂、前瞻性、开放标签影像学研究,纳入47例患者共196个病灶,所有参与者均在基线和18个月随访时接受冠状动脉CTA和18F-NaF PET检查。

关键影像表现/征象

  • 冠状动脉CTA示非钙化斑块体积从607.3 ± 346.8 µL降至562.1 ± 337.3 µL,差值45.2 ± 63.8 µL,P<0.001。
  • 低衰减非钙化斑块体积从37.1 ± 28.9 µL降至20.4 ± 15.4 µL,差值16.6 ± 23.5 µL,P<0.001。
  • 钙化斑块体积从108.9 ± 133.7 µL增至148.7 ± 175.3 µL,差值39.8 ± 56.1 µL,P<0.001。
  • 总斑块体积从716.2 ± 431.4 µL至710.8 ± 456.2 µL,差值5.4 ± 97.4 µL,P=0.705,无显著变化。

诊断标准与关键数值

  • 基线入组标准为冠状动脉CTA显示广泛非钙化斑块体积:整体冠状动脉>440 µL或任一单个斑块>250 µL。
  • 疾病活动度以18F-NaF PET在病灶水平的最大靶本比及全冠状动脉树的冠状动脉微钙化活性评估。
  • 冠状动脉微钙化活性从1.35 ± 1.68降至1.08 ± 1.37,P=0.004。
  • 病灶靶本比从1.73 ± 0.85降至1.62 ± 0.83,P=0.005。

临床应用与阅片要点

  • 对基线广泛非钙化斑块患者,随访冠状动脉CTA可观察到非钙化及低衰减非钙化斑块体积减少、钙化斑块体积增加。
  • 18F-NaF PET所示冠状动脉微钙化活性及病灶靶本比在18个月随访时降低,可作为斑块活动度评估的影像指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: The effects of evolocumab on the underlying coronary disease activity by positron emission tomography (PET) and coronary tree plaque composition by coronary computed tomography angiography (CTA) have not been described.

OBJECTIVES: This prospective imaging study aimed to evaluate changes in coronary plaque composition on coronary CTA and coronary microcalcification, a marker of plaque activity, on 18F-sodium fluoride (NaF) positron emission tomography (PET) after evolocumab treatment.

METHODS: This single-arm, prospective, open-label study enrolled patients with baseline extensive noncalcified plaque volume by coronary CTA (>440 µL overall coronary artery or >250 µL in any single plaque). All participants underwent baseline and 18-month follow-up coronary CTA and 18F-NaF PET. Disease activity was evaluated with 18F-NaF PET by maximum target-to-background ratios at the lesion level and by coronary microcalcification activity for the entire coronary tree.

RESULTS: A total of 47 patients (age 61.8 ± 10.1 years, 87% male) and 196 lesions were studied. Twenty-three (48.9%) patients were asymptomatic, 16 (34%) presented with chest pain, and 8 (17%) presented with dyspnea. Four (8.5%) patients had a prior coronary artery disease history. At a mean follow-up of 18 months, there was no significant change in total plaque volume (716.2 ± 431.4 µL to 710.8 ± 456.2 µL, difference: 5.4 ± 97.4 µL; P = 0.705). Changes in plaque composition were observed, with a significant reduction in noncalcified plaque (607.3 ± 346.8 µL to 562.1 ± 337.3 µL, difference: 45.2 ± 63.8 µL; P < 0.001) and low-attenuation noncalcified plaque (37.1 ± 28.9 µL to 20.4 ± 15.4 µL, difference: 16.6 ± 23.5 µL; P < 0.001). In contrast, there was an increase in calcified plaque (108.9 ± 133.7 µL to 148.7 ± 175.3 µL, difference: 39.8 ± 56.1 µL; P < 0.001). There was a significant reduction in coronary microcalcification activity (1.35 ± 1.68 to 1.08 ± 1.37; P = 0.004) and lesion target-to-background ratio (1.73 ± 0.85 to 1.62 ± 0.83; P = 0.005).

CONCLUSIONS: In stable patients with extensive noncalcified plaque volume at baseline, 18 months of evolocumab treatment was associated with a shift toward a lower risk quantitative plaque phenotype and reduction in microcalcification activity. (Effect of Evolocumab on Coronary Atherosclerosis; NCT03689946).

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Han D, Tzolos E, Park R, et al. Effects of Evolocumab on Coronary Plaque Composition and Microcalcification Activity by Coronary PET and CT Angiography. JACC Cardiovasc Imaging. 2025. PMID: 40178463. doi:10.1016/j.jcmg.2025.01.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。